Navigation Links
Talecris Biotherapeutics Receives FDA Approval for PROLASTIN(R)-C
Date:10/19/2009

RESEARCH TRIANGLE PARK, N.C., Oct. 19 /PRNewswire-FirstCall/ -- Talecris Biotherapeutics (Nasdaq: TLCR) today received approval from the U.S. Food and Drug Administration for PROLASTIN®-C (Alpha1-Proteinase Inhibitor [Human]), a more concentrated version of PROLASTIN® produced using advances in manufacturing technology.

Like PROLASTIN, the market leader for over 20 years, PROLASTIN-C is indicated for the treatment of alpha1-antitrypsin (AAT) deficiency, a genetic condition in which low levels of this essential protein can result in emphysema. The active protein in PROLASTIN-C increases or "augments" protein levels in AAT-deficient patients at risk for developing emphysema.

PROLASTIN-C delivers twice the active protein per milliliter as PROLASTIN, cutting infusion volume and time in half when given at the recommended rate of 0.08 mL/kg/min. Clinical studies have shown that PROLASTIN-C and PROLASTIN are equally effective at raising AAT levels in the blood, and that the adverse event profile of PROLASTIN-C is consistent with that of PROLASTIN. The most common drug-related adverse reactions observed at a rate of >/=1% in subjects receiving PROLASTIN-C were chills, malaise, headache, rash, hot flush and pruritus.

"The introduction of PROLASTIN revolutionized care for thousands of individuals with Alpha-1," said John Walsh, president and CEO of the Alpha-1 Foundation. "We welcome PROLASTIN-C as an example of the ongoing commitment Talecris has made to the Alpha-1 community."

The manufacturing process for PROLASTIN-C incorporates technological advances such as nanofiltration, a virus exclusion technology, and cation exchange chromatography, an additional purification step.

"PROLASTIN-C is an example of the significant investments Talecris is making in research and development and manu
'/>"/>

SOURCE Talecris Biotherapeutics
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Protalix BioTherapeutics Treats First Patient in Phase III Clinical Trial of prGCD
2. Northwest Biotherapeutics Conducting Ovarian Cancer Clinical Trial With DCVax(R)-L at University of Pennsylvania
3. Juvaris BioTherapeutics Announces Cooperative Research and Development Agreement With The Centers for Disease Control and Prevention
4. Protalix BioTherapeutics Extends Research Agreement With Yissum Based on Promising Acetylcholinesterase Program Results in Animal Study
5. Oxygen Biotherapeutics, Inc. Receives Letter From FDA Outlining Path Forward to Resume Oxycyte Clinical Trials in TBI in U.S.A.
6. Oxford BioTherapeutics and GlaxoSmithKline Form Strategic Alliance to Develop Novel Cancer Therapeutic Antibodies
7. Oxygen Biotherapeutics, Inc. Submits Milestone Achievement Notice to Vatea Fund
8. Oxygen Biotherapeutics, Inc. Receives Phase II Trial Approval in Israel
9. Oxygen Biotherapeutics, Inc. to Webcast Shareholder Meeting
10. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
11. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... DUBLIN , Dec. 18, 2014 Research ... announced the addition of the "Micro Market ... report to their offering. ... dermatological treatment is progressing steadily, which has resulted ... diagnostic devices market. The main purpose of these ...
(Date:12/19/2014)...  RESMED INC. (NYSE: RMD ) today announced ... 2015 results on Thursday, January 22, 2015, after the New ... results will be issued after 1:00 p.m. US Pacific Time ... results and future outlook. The earnings call is ... the live webcast of the call can be accessed on ...
(Date:12/19/2014)... LYON, France , Dec. 19, 2014 /PRNewswire/ ... and Adocia (Euronext Paris: FR0011184241 – ADOC) today announced ... insulin, known as BioChaperone Lispro, for treatment in people ... relies on Adocia,s proprietary BioChaperone® technology and is currently ... will develop BioChaperone Lispro with the goal of optimizing ...
Breaking Medicine Technology:Micro Market Monitor: North American Dermatology Diagnostic Devices Market 2Micro Market Monitor: North American Dermatology Diagnostic Devices Market 3ResMed To Announce Second Quarter 2015 Results 2Lilly and Adocia Announce Alliance to Co-Develop Ultra-Rapid Insulin Based on BioChaperone Technology 2Lilly and Adocia Announce Alliance to Co-Develop Ultra-Rapid Insulin Based on BioChaperone Technology 3
... Ore., May 13 Dried blood spots are ... and transport,for blood tests. In an article published ... and Technology (2008; 2(2):242-3), Ramakrishnan Lakshmy,PhD, explains that ... "powerful tool", for,mass disease screening programs, especially in ...
... Clinical Study Initiated Following Success with 8 Patients, ... (OTC,Bulletin Board: DSCI), a provider of advanced wound ... and thoracic surgeons from the,University of Wurzburg, Germany, ... with deep sternal wound infections (DSWI), a,condition that ...
Cached Medicine Technology:Blood Spot Technology at ZRT Highlighted in March Issue of Journal of Diabetes Science & Technology - A Convenient Alternative to Serum Testing for Health Screening 2Cardiovascular Researchers Use MEDIHONEY(TM) on Sternal Infections Following Open-Heart Procedures 2Cardiovascular Researchers Use MEDIHONEY(TM) on Sternal Infections Following Open-Heart Procedures 3
(Date:12/20/2014)... (PRWEB) December 20, 2014 The aftermath of ... quite a stir, not only in Hollywood, but worldwide. ... 18th , the ripples of that attack are starting a ... jobs at risk. But they are not the only ... could be in for some embarrassing times ahead, agents and ...
(Date:12/20/2014)... 20, 2014 The Twin Cities DI ... event in the nation! Over 250 financial professionals come ... information on the industry, get motivated to protect their ... people facing and overcoming the challenges of disability. , ... the nation came together to attend The 13th Annual ...
(Date:12/19/2014)... (PRWEB) December 20, 2014 It’s very easy ... is something that is put to the wayside until Christmas ... still have that travel “itch” and that burning desire to ... accommodates families on their journey to Telluride with a no-fuss, ... visitors to and from the resort, and ensure that all ...
(Date:12/19/2014)... (PRWEB) December 19, 2014 ... dedicated to developing educational events, tools and resources ... Rouxbe Cooking School , the world’s leading online ... prescription every human being needs: Culinary Rx. As ... cooking course, Culinary Rx, scheduled for debut spring ...
(Date:12/19/2014)... These vanadium reserves are mostly found in ... tons of vanadium were produced globally in 2013, up ... at 6.7% AAGR during the period from 2001 to ... the largest consumer, accounted for more than 90% of ... and the chemical industry. , View Full Report at ...
Breaking Medicine News(10 mins):Health News:Sony Pictures Hack Perfect Example of the Reach a Single Cyber Attack Can Have 2Health News:Sony Pictures Hack Perfect Example of the Reach a Single Cyber Attack Can Have 3Health News:Sony Pictures Hack Perfect Example of the Reach a Single Cyber Attack Can Have 4Health News:Sony Pictures Hack Perfect Example of the Reach a Single Cyber Attack Can Have 5Health News:The 13th Annual Twin Cities DI Day Now On Video 2Health News:The 13th Annual Twin Cities DI Day Now On Video 3Health News:Days Inn Montrose Colorado Delivers Last Minute Holiday Season Ski Getaway Accommodations 2Health News:The Plantrician Project and the Rouxbe Cooking School Join Forces to Develop Culinary Rx – a Plant-Prescription Course 2Health News:The Plantrician Project and the Rouxbe Cooking School Join Forces to Develop Culinary Rx – a Plant-Prescription Course 3Health News:The Plantrician Project and the Rouxbe Cooking School Join Forces to Develop Culinary Rx – a Plant-Prescription Course 4Health News:Marketresearchreports.biz: Global Vanadium Usage Increased at AAGR of 6.7% between 2001 and 2013 2Health News:Marketresearchreports.biz: Global Vanadium Usage Increased at AAGR of 6.7% between 2001 and 2013 3
... RIO DE JANEIRO , Jan. ... < GO >; Reuters: AMIL3 SA), the largest managed,care organization ... and,Exchange Commission) Instruction 358/02, informs that was approved in Board,Meeting ... restricted selling efforts (according to CVM Instruction 476/09), with,the objective ...
... group target use of cell phones and texting devices, ... 500,000 people were injured and nearly 6,000 people were ... who was distracted while using a cell phone or ... , To cut down on the growing number of ...
... , , WEST PALM BEACH, Fla. , ... Conference Korea ( http://www.asiamedicaltourismcongress.com ) will take place April, 13-16th, ... the Medical Tourism Association (MTA) and Korea Health Industry Development ... destinations for medical tourism and global healthcare in the world. ...
... Experimental med looks promising, researchers say , TUESDAY, ... may help prevent esophageal cancer, a new study shows. ... treatment of Alzheimer,s disease, is known to have side ... cells that line the colon are similar to those ...
... as 50 per cent of people bring their work home ... University of Toronto that describes the stress associated with work-life ... the extent to which work was interfering with personal time ... Sociology professor Scott Schieman (UofT) and his coauthors Melissa Milkie ...
... their meds, researchers say , TUESDAY, Jan. 12 (HealthDay ... to long-term treatment with cholesterol-lowering statins could prevent twice ... researchers say. , It,s estimated that only about half ... still taking them five years later, according to background ...
Cached Medicine News:Health News:FocusDriven Seeks to Crack Down on Distracted Drivers 2Health News:Global Healthcare & Medical Tourism Conference Korea Announced for April 13-16th, 2010 2Health News:Global Healthcare & Medical Tourism Conference Korea Announced for April 13-16th, 2010 3Health News:When work interferes with life 2Health News:Long-Term Statin Use Best Way to Cut Cardiovascular Deaths 2
Inoculum Broth with Calcium Chloride and Phytone....
12% Tryptone, 24% Yeast Extract, 4.0% Glycerol. Supplied with 1 liter of 10x phosphate buffer (0190-1L)....
10% Casein digest (NZ amine), 5.0% Sodium Chloride, 5.0% Yeast Extract....
0.5% Yeast Extract, 2.0% Tryp, 10mM Sodium Chloride, 2.5mM Potassium Chloride, 10mM Magnesium Chloride, 10mM Mag. Sulfate....
Medicine Products: